Daxdilimab by Horizon Therapeutics for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Daxdilimab overview

Daxdilimab (VIB-7734, MEDI-7734) is under development for the treatment of type I interferon-mediated autoimmune diseases including systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, anti-synthetase inflammatory myositis, lupus nephritis and alopecia areata. It is administered through intravenous and subcutaneous route. It is a monoclonal antibody that binds to an extracellular domain of human ILT7. The drug candidate is developed based on dendritic cell platform.

It was also under development for COVID-19-related pneumonia and acute lung injury and polymyositis, Sjogren’s syndrome, systemic sclerosis. 

Horizon Therapeutics overview

Horizon Therapeutics formerly Horizon Pharma, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Uplinza, Tepezza and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.

For a complete picture of Daxdilimab’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.